Alexandria Real Estate-backed Acrivon has filed to go public while H2 Green Steel increased its corporate-backed series B round to $255m.
Public markets
Acrivon Therapeutics, the US-based oncology therapy developer backed by life sciences real estate investment trust Alexandria Real Estate Equities, has filed for an initial public offering on the Nasdaq Global Market. Its overall funding stood at over $115m as of November 2021.
Reverse merger
Oculis, the Switzerland-based eyesight treatment developer backed by pharmaceutical firm Novartis and property developer Nan Fung, is…
